Abstract:As new mutations continue to emerge, the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus to evade the human immune system and neutralizing antibodies remains a huge challenge for vaccine development and antibody research. The majority of neutralizing antibodies have reduced or lost activity against SARS-CoV-2 variants. In this study, we reported a novel protein surface display system on a mammalian cell for obtaining a higher-affinity antibody in high-throughput manner. Using a saturation mutagenesis strategy through integrating microarray-based oligonucleotide synthesis and single-cell screening assay, we generated a group of new antibodies against diverse prevalent SARS-CoV-2 variants through high-throughput screening the human antibody REGN10987 within 2 weeks. The affinity of those optimized antibodies to seven prevalent mutants was greatly improved, and the EC50 values were no higher than 5 ng/mL. These results demonstrate the robustness of our screening system in the rapid generation of an antibody with higher affinity against a new SARS-CoV-2 variant, and provides a potential application to other protein molecular interactions. The COVID-19 pandemic caused by SARS-CoV-2 has become a global health problem of wide concern due to the continuous emergence of mutants, so that human social and economic activities have suffered a serious blow. The development of potent neutralizing antibodies is critically important in the coming time. At present, the main way to obtain effective neutralizing antibodies against SARS-CoV-2 and its variants is to isolate the serum of convalescent patients or immunized humanized mice. However, this method has high requirements on samples, and the whole process is time-consuming and labor-intensive. We here report a single-cell screening assay that allows the rapid and high-throughput optimizing of a human antibody displayed on a mammalian cell surface. The process can improve the affinity of antibodies with EC50 below 5 ng/mL within 2 weeks. Our approach with short turnaround and significant enhancement in antibody affinity presents an effective strategy for fighting against the ever-evolving COVID variants.

A rapid novel strategy for screening of antibody phage libraries for production, purification, and functional characterization of amber stop codons containing single‐chain antibody fragments

Identification of an anti–SARS–CoV-2 receptor-binding domain–directed human monoclonal antibody from a naïve semisynthetic library

The variable conversion of neutralizing anti-SARS-CoV-2 single-chain antibodies to IgG provides insight into RBD epitope accessibility

Peptide-Antibody Fusions Engineered by Phage Display Exhibit an Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants

A novel lentiviral scFv display library for rapid optimization and selection of high affinity antibodies.

Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy

Nanobodies against SARS-CoV-2 RBD from a Two-step Phage Screening of Universal and Focused Synthetic Libraries

An amber-encoding helper phage for more efficient phage display of noncanonical amino acids

Mammalian cell display with automated oligo design and library assembly allows for rapid residue level conformational epitope mapping

A compact phage display human scFv library for selection of antibodies to a wide variety of antigens

Designing and bioengineering of CDRs with higher affinity against receptor-binding domain (RBD) of SARS-CoV-2 Omicron variant

In Silico Antibody Mutagenesis for Optimizing Its Binding to Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2

Phage Display-Derived Peptide for the Specific Binding of SARS-CoV-2

Improved Soluble ScFv ELISA Screening Approach for Antibody Discovery Using Phage Display Technology

A rapid cell-free expression and screening platform for antibody discovery

The Rapid and Highly Parallel Identification of Antibodies with Defined Biological Activities by SLISY

High-throughput saturation mutagenesis generates a high-affinity antibody against SARS-CoV-2 variants using protein surface display assay on a human cell

A Fully Human Scfv Phage Display Library for Rapid Antibody Fragment Reformatting.

De novo design and Rosetta‐based assessment of high‐affinity antibody variable regions (Fv) against the SARS‐CoV‐2 spike receptor binding domain (RBD)

Development of a Single-Chain Fragment Variable that Binds to the SARS-CoV-2 Spike Protein Produced by Genetically Modified Lactic Acid Bacteria

Antibody Binding Site Mapping Of Sars-Cov Spike Protein Receptor-Binding Domain By A Combination Of Yeast Surface Display And Phage Peptide Library Screening